Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Catalyst: Methods Post-Market DSE - Bayesian methods and statistical models

McMaster University

$100,000.00

Leveraging post-market big data using Integrative Statistical Methods: advancing Drug Safety and effectiveness research (The InStaMeDS Project)

FY 2014-15

Summary
Knowledge gained about drug safety and effectiveness from clinical trials, though essential, does not fully extend to the population. Post-market follow-up is critical to understand long-term effects of drugs and there is a wealth of publicly available data documenting adverse drug reactions. Similarly, massive molecular data are increasingly being generated to identify drugs that may be toxic to certain organs such as the liver and kidney. We will use big data that are readily available and generate new knowledge about drug safety by applying novel analytical methods.
Program
Catalyst: Methods Post-Market DSE - Bayesian methods and statistical models
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
327713
Name
Beyene Joseph
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Drug Safety and Effectiveness Research Methods
Projecttitle
Leveraging post-market big data using Integrative Statistical Methods: advancing Drug Safety and effectiveness research (The InStaMeDS Project)
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Catalyst: Methods Post-Market DSE - Bayesian methods and statistical models
Keyworddelim
Association Rules; Integrative Analysis; Post-Market Drug Safety; Sparse Canonical Correlation Analysis; Toxicogenomics
Abstract
Knowledge gained about drug safety and effectiveness from clinical trials, though essential, does not fully extend to the population. Post-market follow-up is critical to understand long-term effects of drugs and there is a wealth of publicly available data documenting adverse drug reactions. Similarly, massive molecular data are increasingly being generated to identify drugs that may be toxic to certain organs such as the liver and kidney. We will use big data that are readily available and generate new knowledge about drug safety by applying novel analytical methods.
Competitiondate
201501
Approvedterm2
1 yr 0 mth
Pinamesdelim
Beyene, Joseph
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~